- Home
- IHD vs AVTX Comparison
IHD vs AVTX Comparison
Compare IHD & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IHD | AVTX |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.5M | 339.9M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | IHD | AVTX |
|---|---|---|
| Price | $6.47 | $13.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $32.57 |
| AVG Volume (30 Days) | 142.5K | ★ 592.2K |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | ★ 10.32% | N/A |
| EPS Growth | N/A | ★ 72.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,813,137.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2312.27 |
| 52 Week Low | $4.54 | $3.39 |
| 52 Week High | $7.28 | $20.72 |
Technical Indicators
Market Signals| Indicator | IHD | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 42.90 | 34.46 |
| Support Level | $5.82 | $13.45 |
| Resistance Level | $7.19 | $16.40 |
| Average True Range (ATR) | 0.14 | 1.05 |
| MACD | -0.01 | -0.46 |
| Stochastic Oscillator | 50.29 | 7.91 |
Price Performance
Historical ComparisonAbout IHD Voya Emerging Markets High Income Dividend Equity Fund
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).